Praxis Precision Medicines (PRAX) Expected to Announce Earnings on Tuesday

Key Points

• Praxis Precision Medicines is anticipated to report Q2 2025 earnings on August 12, with expected losses of ($3.40) per share and revenue of $0.16 million.
• Analysts forecast a negative net margin of 2,137.48% and a return on equity of -50.42% for the company, with forecasts of $-10 EPS for the current fiscal year.
• Several firms have given varying ratings on PRAX, leading to a consensus rating of "Moderate Buy" and a target price of $95.22.

Praxis Precision Medicines (NASDAQ:PRAX - Get Free Report) is expected to be announcing its Q2 2025 & Study Result earnings results before the market opens on Tuesday, August 12th. Analysts expect the company to announce earnings of ($3.40) per share and revenue of $0.16 million for the quarter.

Praxis Precision Medicines (NASDAQ:PRAX - Get Free Report) last issued its quarterly earnings results on Monday, August 4th. The company reported ($3.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.40) by $0.09. Praxis Precision Medicines had a negative net margin of 2,137.48% and a negative return on equity of 60.07%. On average, analysts expect Praxis Precision Medicines to post $-10 EPS for the current fiscal year and $-12 EPS for the next fiscal year.

Praxis Precision Medicines Trading Down 2.8%

Shares of PRAX stock traded down $1.33 during trading hours on Friday, hitting $45.94. 438,540 shares of the company were exchanged, compared to its average volume of 543,862. The firm has a fifty day simple moving average of $48.11 and a 200 day simple moving average of $48.27. Praxis Precision Medicines has a 52-week low of $26.70 and a 52-week high of $91.83. The stock has a market capitalization of $967.04 million, a price-to-earnings ratio of -3.74 and a beta of 2.62.

Institutional Trading of Praxis Precision Medicines

Hedge funds and other institutional investors have recently made changes to their positions in the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Praxis Precision Medicines by 367.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 87,081 shares of the company's stock worth $3,298,000 after buying an additional 68,466 shares in the last quarter. Creative Planning purchased a new stake in Praxis Precision Medicines during the second quarter worth $273,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Praxis Precision Medicines by 5.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 11,708 shares of the company's stock worth $444,000 after buying an additional 573 shares in the last quarter. Institutional investors and hedge funds own 67.84% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on PRAX shares. Oppenheimer lifted their price objective on shares of Praxis Precision Medicines from $97.00 to $115.00 and gave the stock an "outperform" rating in a report on Tuesday, July 8th. Chardan Capital restated a "buy" rating and issued a $80.00 price objective on shares of Praxis Precision Medicines in a research report on Tuesday, July 29th. HC Wainwright reiterated a "buy" rating and set a $115.00 price target (up previously from $105.00) on shares of Praxis Precision Medicines in a research report on Tuesday. Needham & Company LLC restated a "buy" rating and issued a $80.00 price objective on shares of Praxis Precision Medicines in a report on Thursday, June 12th. Finally, Wedbush upped their target price on shares of Praxis Precision Medicines from $26.00 to $28.00 and gave the stock an "underperform" rating in a research note on Monday, May 5th. One equities research analyst has rated the stock with a sell rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $95.22.

Praxis Precision Medicines Company Profile

Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.